Neuroleptics and the corpus striatum: clinical implications.
D000109:Acetylcholine / Q000502:physiology; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001590:Benztropine / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects*; D004298:Dopamine / Q000502:physiology; D005476:Fluphenazine / Q000627:therapeutic use; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008959:Models, Neurological; D009069:Movement Disorders / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D012110:Reserpine / Q000494:pharmacology; D012559:Schizophrenia / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000627:therapeutic use
D014149:Tranquilizing Agents; D001590:Benztropine; D007980:Levodopa; D014282:Trihexyphenidyl; D012110:Reserpine; D006220:Haloperidol; D000109:Acetylcholine; D005476:Fluphenazine; D004298:Dopamine